DUBLIN–(BUSINESS WIRE)–The “Cytokine
Market – Growth, Trends, and Forecast (2019 – 2024)” report has
been added to ResearchAndMarkets.com’s offering.
Key Market Trends
The ‘Other Applications Segment’ in Therapeutic Applications is
Expected to Hold the Largest Share over the Forecast Period
The other applications segment includes diseases, like multiple
sclerosis, psoriasis, ankylosing spondylitis, and inflammatory bowel
disease. The inhibition of TNF using various blocking mediators has
proven to be an effective therapy for patients with various forms of
inflammatory disease, including psoriasis, psoriatic arthritis,
ankylosing spondylitis, and inflammatory bowel disease. High TNF levels
play a significant role in the raised, red skin plaques that come with
psoriasis.
Cytokines are important in the pathogenesis of IBD, and their
manipulation has successfully reduced disease severity and maintained
remission. The approval of IL-17A-blocking biologics for the treatment
of moderate-to-severe plaque psoriasis is a positive indicator for
market development. However, further studies are being conducted to
improve the efficacy of these treatments.
North America Holds the Largest Market Share
North America is dominating the cytokine market, due to the rising
prevalence of cancer in the region. Numerous animal tumour model studies
have demonstrated that cytokines have broad anti-tumour activity, which
has been translated into a number of cytokine-based approaches for
cancer therapy. As per the Cancer Statistics, in 2016, an estimated 1.6
million new cases of cancer were diagnosed in the United States, with
prevalence expected to rise to almost 19 million by 2024.
Augmenting growth in the R&D of cancer therapy, along with lesser side
effects (as compared to chemotherapy), has predisposed cytokine therapy,
which is a non-specific immunotherapy. This factor has increased the
market share of cytokines among cancer therapies, in the United States.
Competitive Landscape
The cytokine market consists of several major players. The companies are
implementing certain strategic initiatives, such as a mergers, new
product launches, acquisitions, and partnerships, which help them in
strengthening their market position. For instance, in October 2017, US
FDA approved Stelara (ustekinumab) for the treatment of adolescents with
moderate-to-severe plaque psoriasis, which is developed by Janssen
Pharmaceutica.
Key Topics Covered
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Acceptance in Cancer Therapy
4.2.2 Potential Biomarker for Neonatal Sepsis
4.2.3 Potential Contribution in Stem Cell Therapy
4.3 Market Restraints
4.3.1 Extensive Investments
4.3.2 Lacks Specificity
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Cytokine Type
5.1.1 Tumor Necrosis Factor-TNF
5.1.2 Interleukins-Il
5.1.3 Interferons-IFN
5.1.4 Epidermal Growth Factor-EGF
5.1.5 Other Cytokine Types
5.2 By Therapeutic Application
5.2.1 Cancer
5.2.2 Asthma and Airway Inflammation
5.2.3 Arthritis
5.2.4 Other Therapeutic Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline
6.1.2 Novartis
6.1.3 Roche
6.1.4 Pfizer
6.1.5 Sanofi
6.1.6 Bayer Healthcare Pharmaceuticals
6.1.7 Thermo Fisher Scientific
6.1.8 Biocon
6.1.9 Biotechne
6.1.10 Abbvie
6.1.11 Johnson & Johnson
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/gmqtxb
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biopharmaceuticals